The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
|Videos|July 5, 2017
Dr. Kumar Discusses Ixazomib in Multiple Myeloma
Author(s)Shaji K. Kumar, MD
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.
Advertisement
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.
The proteasome inhibitor ixazomib is being evaluated in combination with lenalidomide (Revlimid) and dexamethasone in patients with newly diagnosed multiple myeloma.
Advertisement
Related to this article
An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.
Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.
Teclistamab-based induction generated a 91.8% MRD-negative complete response rate with a manageable safety profile in multiple myeloma.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 8/23
3
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
4
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
5